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Short running head: Loss-rich and gain-rich lineages in GC 
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Abstract 
Background: To examine whether gastric carcinoma (GC) with chromosomal instability 
(CIN-type GC), the largest category in the Cancer Genome Atlas classification, consists of a 
single genetic lineage, we conducted a multisampling analysis of genomic DNA copy-number 
profile. Methods: We performed array-based comparative genomic hybridization using 
formalin-fixed, paraffin embedded tissues from 54 gland-forming GCs containing a total of 
106 DNA samples from mucosal, extra-mucosal invasive, and lymph node lesions. 
Microarray data were analyzed by unsupervised hierarchical clustering and penetrance plots. 
Epstein-Barr virus infection status and mismatch repair (MMR) enzyme silencing/p53/mucin 
expression were examined with in situ hybridization and immunohistochemistry, respectively. 
Results: The samples examined were divided into gain-rich clusters A and loss-rich cluster B, 
which were different in tumor locus and patient age. The T1/T2–4 ratio, the frequency of 
small cancers (diameter ≤2–4 cm), and intestinal mucin expression were higher in cluster B 
than in cluster A, whereas there were no significant differences in the frequencies of MMR 
silencing, mutant p53 pattern, and lymph node metastasis between the two clusters. 
Conclusions: We demonstrated that the CIN-type GC could be categorized into two genetic 
lineages which were different in rapidity of local extension but similar in nodal metastasis 
risk.  
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Introduction 
Gastric carcinoma (GC) is the fifth most common malignant neoplasm and the third leading 
cause of cancer-related deaths in both sexes worldwide [1]. Recently, the Cancer Genome 
Atlas (TCGA) classification of GC includes four subtypes: Epstein-Barr virus (EBV)-positive 
GCs, microsatellite-unstable GCs, genomically stable GCs, and GCs with chromosomal 
instability (CIN) [2]. It remains unclear how the risk of progression from early to advanced 
stage or metastasis risk is assessable and whether the most common CIN-type GCs are 
genetically homogeneous.  
Early GC is defined as a tumor that is limited to the mucosal and submucosal layers, if 
present, irrespective of the lymph node status. In Japan, early GCs account for approximately 
40%–60% of all GC cases [3-5], most of which are detected by endoscopy. Endoscopic 
resection (ER) of early GCs, which has become the standard treatment in Japan, is gaining 
greater acceptance worldwide [6]. However, indications for ER of early GC are limited to 
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those with a very low risk of lymph node metastasis; gland-forming tumors ≤ 2 cm at clinical 
pT1a stage [7]. When the ESD specimen is pathologically assessed as non-curative, 
additional treatment follows to prevent recurrence. However, the subsequently removed 
gastric tissue frequently do not show any evidence of tumor spread or metastasis.  
The extent to which early detection and treatment contribute to the reduction of mortality 
in these patients depends on the lineage continuity between the endoscopically resectable 
lesions and advanced cancer. In our previous studies, we applied genomic DNA copy-number 
alteration (CNA) profiling to precursor lesions as well as early and advanced GC specimens, 
and classified GC samples using unsupervised hierarchical cluster analyses. Using this 
approach, we have demonstrated that virtually all undifferentiated (diffuse) early GC cases 
were considered to become advanced [8], whereas around 20% of non-invasive (gland-
forming) neoplasms were considered to eventually become invasive [9]. In the present study, 
we utilized this approach to multiple samples from mucosal, extra-mucosal invasive, and 
metastatic lymph node lesions of individual tumor specimens to confirm the consistency of 
individual-specific changes and to examine changes associated with tumor progression.  
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Patients and Methods 
Materials 
This study used formalin-fixed paraffin embedded tissue specimens from 57 invasive 
gastric adenocarcinomas including 22 intramucosal, 6 submucosal (including 1 collision 
cancer, counted as 2 distinct tumors), and 29 advanced cancers (including 2 double cancers, 
each counted as 2 tumors) (online suppl. Table 1). Of these tumors, 25 lymph node-positive 
(N+) and 22 node-negative (N0) tumors were surgically resected from 44 patients in the 
period between 1998 and 2014, and 10 mucosal GCs (cases M27 to M36; online suppl. Table 
1) were removed by ESD during the 2012–2014 period. For diagnosis of N0 tumors, 10 or 
more lymph nodes examined had to be free from metastasis [10]. We performed 
multisampling, including mucosal, invasive, and if present, lymph node metastatic samples in 
all 27 advanced GC cases included in this study. The third edition of the Japanese 
Classification of Gastric Carcinoma and pTNM staging were used to determine histological 
characteristics and tumor stages, respectively [11]. 
Immunohistochemistry and EBV in situ hybridization  
Immunohistochemical staining of 4-µm-thick paraffin sections was performed using an 
automated Ventana Discovery XT system (Tucson, AZ, USA) with heat pretreatment, an 
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amplification kit (Ventana, 760-080) and a DAB detection kit (Ventana, 760-124). The 
following two monoclonal antibodies against two mismatch repair (MMR) proteins were 
used to assess enzyme silencing, which is closely related to microsatellite instability (MSI) 
[12]: MSH6 (clone 44, Ventana) and PMS2 (clone EPR3947, Cell Marque, Rocklin, CA, 
USA). A monoclonal antibody to p53 protein (DO-7, 1:100; Dako, Glostrup, Denmark) was 
used to assess p53 expression pattern. Mucin phenotype was analyzed 
immunohistochemically using monoclonal antibodies against MUC2 (clone MRQ-18, Cell 
Marque, Rocklin, CA, USA), MUC5AC (clone MRQ-19, Cell Marque), MUC6 (clone MRQ-
20, Cell Marque) and CD10 (clone 56C6, Dako, Glostrup, Denmark). The stains were scored 
according to the percentage of stained neoplastic cells and categorized into gastric (G), 
intestinal (I), null (N), G>I, and I>G phenotypes based on the previous study [9]. A 
polyclonal antibody to SEMA3E protein (1:500; Atlas Antibodies, Bromma, Sweden) to 
evaluate the expression of SEMA3E gene.  
Loss of MMR enzyme expression (LOM) was defined as complete absence of tumor 
nuclear staining in specimens with retention of MMR enzyme expression (ROM) in nuclei of 
normal glands and lymphocytes (internal control) [12]. p53 staining pattern was classified as 
diffuse, regional, sporadic, and null. The former two and the last patterns were considered to 
reflect mutation, whereas sporadic pattern was considered as a wild-type (WT) pattern.  
7 
 
EBV status was determined by EBV-encoded small RNA (EBER) in situ hybridization [13] 
using the INFORM EBER Probe (Ventana, 800-2842: Mannheim, Germany). 
Genomic DNA extraction 
Genomic DNA was extracted from 5-µm-thick tumor and normal gland (reference) sections 
using laser microdissection (LMD6000; Leica Microsystems, Wetzlar, Germany). Samples 
were obtained from an area of ≥6 mm2 in which ≥90% of the cells were neoplastic. A 
proteinase K solution (200 µg/ml) was used for digestion of the dissected tumor and reference 
samples for 70 ± 2 h at 37°C, followed by phenol/chloroform DNA extraction. DNA quality 
assessment was based on a cut-off A260/A280 ratio of >1.5, a cut-off A260/A230 ratio of 
>1.0, and concentration of double-stranded DNA. 
Whole genome amplification  
We used the GenomePlex whole genome amplification kit (WGA2 Kit; Sigma, St. Louis, 
MO, USA) for DNA amplification according to the manufacturer’s protocol [14]. 
Array-based comparative genomic hybridization  
For array-based comparative genomic hybridization (aCGH), 60-mer length oligonucleotide 
probes were used according to the manufacturer’s guidelines [15]. From each tumor 
specimen, a set of genomic DNA samples, one from nonneoplastic glands, as a reference, 
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tumor and the others from tumor parts, were labeled using Cyanine 5 and Cyanine 3, 
respectively, prior to competitive microarray hybridization (SurePrint G3 CGH Microarray 
8x60K, GPL10152 62,976 probes). Intensity of all hybridized probes were captured and 
qualified by a DNA microarray scanner (Feature Extraction software 10.7.3.1) followed by 
calculation of the ratio of tumor and reference fluorescence intensities. Next, chromosomal 
patterns within the microarray profiles were visualized, detected, and analyzed by the Agilent 
CGH analytic software using the UCSC Genome Browser according to the latest resource 
content: hg19 assembly-Design ID 021429 (GRCh Build 37). Definition of genomic copy 
number gain and loss, and amplification were based on base 2 logarithm of the tumor-to-
reference (T/R) ratios which were >0.3219, <−0.3219, and >1, respectively. The microarray 
data were registered in the Gene Expression Omnibus (GEO) data base (Accession number: 
GSE108507). 
Clustering algorithm 
Before performing the cluster analysis, average T/R ratio of the probes within each gene was 
calculated to intensify the signal-to-noise ratio in hybridization analysis. Given that samples 
from the same tumor might share random generation of gene CNAs and tissue environmental 
selection, different parts of a tumor might have similar CNA profiles in the presence of a 
common carcinogenetic process [21, 22]. CNA profiles that have a low noise level could 
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satisfy this internal standard. Gene size, which is defined as the number of probes in each 
gene, impacts noise-canceling function of the average of T/R ratio, whereas clustering 
reproducibility depends on the number of genes. For smaller gene numbers, the 
reproducibility of clustering analysis becomes lower, whereas gene size is larger. Thus, for 
determining optimal gene size and number, the clustering analysis was repeatedly performed 
using the Clustering 3.0 (version 1.52) software and TreeView (version 1.1.6r2) [29, 30]. The 
unsupervised clustering analysis was based on genomic copy number profile resemblance, 
and complete linkage and uncentered correlation distance were applied. 
Genes showing significantly different CNAs between clusters 
Welch’s t test was used between average log2(T/R) values of total A cluster and total B 
cluster samples for 14,977 protein-coding genes. Bonferroni correction was used to correct 
for multiple comparisons. 
Statistical analysis 
We used Microsoft Office Excel 2013 and BellCurve for Excel (Social Survey Research 
Information Co., Ltd., Tokyo, Japan). Correlations among variables were examined using 
Fisher’s exact test and Welch’s t test. Statistical significance was determined at a p value of 
less than 0.05.  
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Results 
Unsupervised clustering analysis of the CNA profile 
To improve the CNA signal-to-noise ratios, probe T/R ratios within a specified gene were 
averaged (T/R ratios of 55,142 probes in 30,471 gene regions). To classify the samples solely 
by the similarity in their CNA profile, unsupervised cluster analysis was performed. To 
determine the optimal clustering condition, we repeated the clustering nine times using 
varying gene sizes, from 9,487 genes with ≥2 probes to 370 genes with ≥10 probes, [9] and 
correlated the neighboring or splitting sample distribution in the dendrogram with the 
presence of large chromosomal changes common to all samples for each case, which we 
defined as stemline changes. For this purpose, we prepared penetrance plots of individual 
samples (online suppl. Fig. 1). Of these nine conditions, we chose the condition including 
genes with ≥5 probes because the neighboring sample distribution in the dendrogram was 
best correlated with the presence of stemline changes. In the chosen condition, out of the 27 
cases included in the multisampling, 21 cases showed a neighboring pattern and 6 cases 
showed a splitting pattern in the sample distribution (Fig. 1). Of the 21 neighboring pattern 
cases, stemline chromosomal changes were detected in 17 cases with ROM and not in 4 cases 
with LOM (online suppl. Fig. 1). Of the six splitting pattern cases included two double 
11 
 
cancers (case# A13 and A17), three cancers with almost no common chromosomal changes in 
the samples (case# S5, A15, and A29), and one cancer with stemline changes but splitting 
between the samples with and without 1p/q+ (case# A7).  
Clustering results and their relationship to MMR enzyme expression, p53 
expression, EBV infection, and mucin phenotype 
Consequently, a total of 106 samples were classified into two major clusters: A and B (Fig. 
1). The heat map indicated that there was a copy-number gain area common to both clusters. 
Clusters A and B were characterized by the presence of gain-rich and loss-rich areas, 
respectively. LOM samples characteristically showed dark in the heat map. There were no 
differences in the frequencies of LOM and mutant p53 pattern between the two clusters. The 
LOM samples were not distributed in the clusters. Additionally, we confirmed that MMR 
enzyme silencing and mutant p53 pattern were mutually exclusive (Fig. 1). The tumors we 
examined in this study contain only 1 case with EBV infection. The staining results of mucin 
phenotype are shown in online suppl.Table 1. We found that the relative frequency of gastric 
predominant phenotype (G, G≥I)/null type (N) was significantly lower in invasive/metastatic 
parts than in mucosal parts, whereas intestinal predominant phenotype (I, I>G) was almost 
constant between these parts (online suppl. Fig. 2). Therefore, we can tentatively regard the 
intestinal expression as a progression-independent lineage marker. This marker expression 
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was more common in cluster B than in cluster A. 
Chromosomal CNAs 
The penetrance plots of the tumors with LOM demonstrated infrequent gains (such as 12q+, 
which was rare in the ROM samples) and scarce losses, whereas gains and losses were 
conspicuous in the ROM tumors (Fig. 2a, b), which were divided into two patterns by 
clustering (Fig. 2c, d). The changes common to both clusters were 8q+, 13q+, 20q+, and 5q−. 
Clusters A and B were characterized by gain-rich (7p/q+, Xp/q+, etc.) and loss-rich (4p/q−, 
etc.), respectively (Fig. 2c, d). Statistical analyses are shown in Table 1a. The mucosal, 
invasive, and metastatic ROM samples were compared in clusters A and B (Fig. 3). The 
changes common to clusters A and B (8q+, 13q+, 20q+, and 5q−) were already present in the 
mucosal samples, whereas cluster-specific changes (such as 4p/q− and 7p/q+) accumulated 
during the progression to invasion and metastasis. These were confirmed by statistical 
analysis of the frequency of each chromosomal CNA, which were determined by counting 
using the penetrance plot of each sample (online suppl. Fig. 1) and compared between the 
mucosal and extra-mucosal (invasive and metastatic) samples (Table 1b). In contrast, such 
differences were not detected between the invasive and metastatic samples. Table 1c shows 
metastasis-related chromosomal changes. The chromosomal changes common to clusters A 
and B were not or weakly related to metastasis, whereas the cluster specific changes, such as 
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7p/q+ in cluster A and 3p−, 4p−, 5q−, and 8p− in cluster B were significantly related to 
lymph node metastasis. The chromosomal changes detected are summarized as an 
evolutionary tree in Fig. 4. 
Clinicopathological and molecular characteristics of the clusters 
Clinicopathological characteristics and molecular changes were compared between the 
tumors of clusters A and B (Table 2). The tumor locus and patient age were different between 
clusters A and B. In this tumor-based analysis, representative phenotype in each submucosal 
or advanced cancers was defined to that of the invasive sample, and we could also confirm 
that the intestinal expression was more frequent in cluster B than in cluster A. 
The T1/T2–4 ratio and the frequency of small cancers (diameter ≤ 2–4 cm) were higher in 
cluster B than in cluster A, suggesting that the GCs in cluster A is more rapidly growing than 
in cluster B. Nine of the 10 ESD specimens examined were classified into cluster B. There 
were however no significant differences in the frequencies of lymph node metastasis. 
Genes showing significantly different CNAs between the clusters 
We identified 32 genes that significantly contributed to the difference in clusters A and B. Of 
these genes, 12 were related to growth, as shown in online suppl. Fig. 2. When the gene 
function and the direction of CNAs were consistent, we regard the CNAs as putative driver 
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and when inconsistent, we regard the CNAs as putative passenger. There were five putative 
driver tumor suppressor genes (CACNA2D3, PTPRG, and LRIG1 at chromosome 3p, SLIT2 
at chromosome 4p, and FSTL5 at chromosome 4q) and one possible driver protooncogene 
(semaphorin 3E [SEMA3E]) at 7q. However, immunohistochemically, there was no difference 
in expression level of SEMA3E protein between 10 tumors that showed greatest copy-
number gains and those with greatest copy-number losses. 
To compare the growth activity between cluster A and cluster B tumors, we examined the 
frequency of amplification of growth-related genes, which is a characteristic of CIN-type GC. 
Of the 55 receptor tyrosine kinases (RTKs) examined, copy-number gains of 12 RTKs, 
including EGFR, ERBB3, FGFR4 and EPHB3 and amplification of LMTK2, EPHB3, 
EPHB4 showed significantly different frequency between clusters A and B, and all of them 
were more frequently detected in cluster A than in cluster B (online suppl. Table 2). 
 
 Discussion  
Using the multisampling method, we could demonstrate not only the differences among 
samples but also the reproducibility of changes common to all samples in individual GC 
patients. To assess the reproducibility of this approach as well as to classify samples, we 
applied unsupervised, hierarchical clustering analysis to the multisampling aCGH data of 57 
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early and advanced gland-forming GC specimens. We selected the clustering condition that 
showed the highest concordance between the neighboring pattern in the clustering 
dendrogram and the presence of stemline changes. Even in the absence of stemline changes 
among the samples from individual tumors such as the LOM tumors, the mucosal and 
invasive/metastatic samples of individual tumors often showed a neighboring position in the 
dendrogram, likely reflecting a similarity among gene-level CNAs. CNA profiles are 
considered as individual tumor-specific and progression-independent lineage markers.  
During development of individual tumors, random changes as well as essential genetic and 
epigenetic changes accumulate in a time-dependent manner based on genetic instability, and 
these changes undergo natural selection by the tissue environment. In this evolutionary 
process, genomic alteration profiles might become unique to each individual tumor, which 
might converge in several types by natural selection [16]. We attempted to reveal such 
converged genotypes using unsupervised hierarchical clustering.  
The tumors included in the present analyses were mostly CIN-type and partly MSI-type of 
TCGA classification, whereas EBV-related GCs were infrequent. A cancer with LOM, which 
largely overlaps with the MSI phenotype, is characterized by a low frequency of 
chromosomal changes and the presence of the unique 12q+ (Fig. 2a, b), and may have 
branched off from the main trunk of gland-forming GCs at earlier stages of GC development 
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(Fig. 4). Accordingly, it was reported that GCs of MSI phenotype showed the frequency of 
chromosomal CNAs lower than in GCs without MSI and were associated with high DNA 
methylation status even at intramucosal stages [17]. 
We classified ROM GC samples (GCs excluding LOM) into two clusters, A (ROM) and B 
(ROM) (Fig. 2c, d). Based on the resemblance of gene-level CNA profiles, our clustering 
approach have successfully disclosed two distinct genetic lineages (gain-rich and loss-rich 
lineages) that have not been clearly recognized thus far. In the present study, we analyzed 
sequential accumulation of chromosomal CNAs during progression from the mucosal to the 
invasive/metastatic growth in each lineage (Fig. 3). Both lineages might have derived from 
the common trunk with 8q+, 13q+, 20p/q+, and 5q−,which were commonly detected in both 
clusters A and B. These findings partly confirm the report of Uchida et al., who reported 8p+ 
and 5q− as early changes of GC [18]. Then, cluster-specific later changes, such as 7pq+ in 
cluster A and 4pq− in cluster B (Fig. 4). 
Next, we classified all samples into two clusters, A and B. There appeared little 
relationship between this cluster classification and TCGA GC subtypes (Table 2).The tumor 
locus and patient age were different between clusters A and B. The age difference might be 
explained by the difference in the frequency of early GCs, whereas the locus difference 
suggests that this clustering might reflect distinct genetic lineages. This was also supported 
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by mucin phenotyping; progression-independent intestinal expression was significantly 
different between clusters A and B. Comparison of other clinicopathological factors between 
clusters A and B indicated that the tumors in cluster A was more rapidly growing (larger, 
deeper tumors) than those in cluster B. ESD specimens were mostly included in the latter. 
These finding implied that early detection and treatment were more difficult in cluster A than 
in cluster B tumors (Fig. 5).  
A rapid growth in the gain-rich lineage (cluster A) might be partly due to the copy-number 
gains/amplifications of the RTKs mentioned above and growth-related genes in chromosome 
7, including RalA [19], EGFR [20], MAFK [21], GLI3 [22], CUL1 [23], and SEMA3E [24, 
25] (online suppl. Table 2). Among these, only SEMA3E exhibited significant copy-number 
differences after Bonferroni correction between clusters A and B. However, its expression is 
reportedly enhanced [24] or suppressed [25] in GCs. Our immunohistochemical studies for 
SEMA3E failed to demonstrate significant association between protein expression level and 
gene copy number, and we cannot regard this gene as functional driver or suppressor. Rather, 
detection of immunoreactivity for amplified growth-related genes may be more promising as 
cluster A markers. In the loss-rich lineage (cluster B), the above-mentioned tumor suppressor 
genes on 3p and 4p/q showed significant differences between clusters A and B. In particular, 
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silencing of CACNA2D3 [26] and PTPRG [27] were reported to play a role in gastric 
tumorigenesis.  
There was no significant differences in the lymph node metastasis risk between the rapidly 
and slowly growing lineages, whereas there were lineage-specific, invasion/metastasis-related 
chromosomal changes. These findings suggest that metastasis risk is determined not at an 
earlier but at a later stage during tumor development as shown in Fig. 4.  
These conclusions have several clinical implications for early detection and treatment 
strategies. This study was conducted with a null hypothesis that there are indolent cancers 
treated as cancers, which are associated with very low mortality risk. We previously 
demonstrated that high-grade and low-grade gastric adenomas, of which the former is treated 
as carcinoma in Japan, were such tumors. Only around 20% of these tumors were inferred to 
progress to overt GC [9] (Fig. 5). The present study showed that there was no inherently 
indolent CIN-type early GC cluster and that the two lineages demonstrated in the present 
study had equal potential for metastasis. Our findings also demonstrated that GCs detected at 
an early stage were biased to a slowly growing loss-rich lineage. The prevalent use of early 
detection by endoscopy and subsequent treatment contribute to the reductions in the 
incidence of advanced GC and age-adjusted mortality rates; however, these reduction sizes 
were smaller than expected compared with the reduction in the GC morbidity rate [28]. One 
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major cause might be the increase in the percentage of older patients. Another factor might be 
the failure of early detection of GCs with a rapidly growing gain-rich lineage, which remains 
a challenge that should be addressed in future studies.  
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Figure legends 
Fig. 1: Unsupervised clustering analysis of 106 samples using the genes/markers of ≥5-probe 
size. Genomic copy-number gains and losses of genes/markers are indicated by red and green 
squares, respectively in the clustering heat map. The clustering results are related to tumor 
size (gray squares: ≤2 cm), presence of lymph node metastasis (marked with green 
background of sample names), Mutant pattern (M, purple) of p53 immunohistochemistry 
(WT; Wild type), loss of mismatch repair enzyme expression (LOM, pink), and EBV 
infection status, and mucin phenotype (I/G/N: intestinal/gastric/null). Intestinal predominant 
(I, I > G) and gastric predominant (G, G ≥ I) phenotypes are marked with yellow and brown 
background, respectively.  
 
Fig. 2: Frequency of copy-number alterations at the chromosome level (penetrance plots) 
compared between the tumors with and those without mismatch repair enzyme silencing and 
between clusters A and B. Statistically significant differences are marked with blue frames. a, 
b. LOM: loss of mismatch repair enzyme expression; ROM: retention of mismatch repair 
enzyme expression. The sample numbers of LOM and ROM are 14 and 92, respectively. c, d. 
Clusters A and B consist of 41 and 51 samples, respectively.  
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Fig. 3: Penetrance plots of ROM tumors in clusters A and B. Cluster-specific, progression-
related significant changes are marked with blue frames. a, d. Mucosal samples; b, e. extra-
mucosal invasive samples; c, f. lymph node metastasis samples. The sample numbers of a to f 
are 18, 15, 8, 31, 12, and 8, respectively. 
 
Fig. 4: Evolutionary tree of gland-forming gastric carcinoma reconstructed from the data of 
Table 1, and Figs 2 and 3. LOM/ROM: loss/retention of mismatch repair enzyme expression. 
Chromosomal gains and losses are shown as red and green characters. Bold/normal letters 
indicate frequent/infrequent significant changes. Chromosomal parts in parentheses indicate 
insignificant but characteristic changes. 
 
Fig. 5: Progression model of gland-forming gastric neoplasm from intramucosal neoplasm to 
invasive carcinoma. 
 
Online suppl. Table 1: Clinicopathological features of individual tumors (age, gender, locus, 
size of mucosal lesion, pT, pN, and excision type) and immunohistochemical and in situ 
hybridization results (p53, MMR enzymes, EBV, mucin markers) of individual samples. 
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(xlsx28KB) 
 
Online suppl. Table 2: Frequencies of copy-number gains and amplifications of receptor 
tyrosine kinases and representative growth-related genes on chromosome 7 in clusters A and 
B. (xlsx15KB) 
 
Online suppl. Fig. 1: Penetrance plots of individual samples. The sample orders in clusters A 
and B and LOM corresponds to the sample order in Fig. 1. LOM: loss of mismatch repair 
enzyme expression; ROM: retention of mismatch repair enzyme expression. (pdf282KB) 
 
Online suppl. Fig. 2: Comparison of mucin phenotype composition between mucosal (M) 
and invasive/metastatic (I + LN) samples in the cluster A and the cluster B tumors. Based on 
the online suppl. Table 1, mucin phenotype was classified into gastric predominant phenotype 
(G, G≥I), intestinal dominant phenotype (I, I>G), and unclassifiable phenotype (N). a. mucin 
phenotype composition of M and I + LN parts in clusters A and B. b, c. Statistical analyses of 
the differences in frequency of gastric predominant expression (b) or intestinal predominant 
expression (c) between M and I + LN parts and between clusters A and B. (pdf389KB) 
 
Online suppl. Fig. 3: Outline of 32 genes that showed significantly different copy-numbers 
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between clusters A and B. The mean copy number alterations (CNAs) are expresses as 
Tumor/Reference (T/R) signal intensity ratio. In the gene function column, tumor suppressor 
genes and proto-oncogenes are marked with green and pink background, respectively. In the 
mean T/R ratio columns, copy-number gains and losses are marked with pink and green 
background, respectively. Concordant pairs of CNA and gene function are marked with black 
frame. (xlsx15KB) 
 
 
p value  p value  p value
Cluster A Cluster B M I+LN N1-3 N0
(n = 41 ) (n = 51 ) (n = 53 ) (n = 39 ) (n = 51 ) (n = 41 )
3p− 7 14 0.3192 6 15 0.0028 17 4  0.0114
3q+ 10 6 0.1660 6 10 0.0967 11 5 0.2792
4p− 4 12 0.1020 5 11 0.0260 14 2 0.0097
4q− 2 14 0.0051 8 8 0.5820 13 3 0.0275
5p+ 12 8 0.1339 8 12 0.0805 14 6 0.2035
5q− 8 16 0.2374 11 13 0.2306 19 5 0.0083
7p+ 23 7 <0.0001 9 21 0.0003 24 6 0.0015
7q+ 12 2 0.001 3 11 0.0064 13 1 0.0025
8p− 6 16 0.0853 7 15 0.0067 19 3 0.0011
8q+ 19 23 1.0000 23 19 0.6746 25 17 0.5309
9p− 7 17 0.0969 9 15 0.0300 18 6 0.0320
10p+ 12 7 0.0763 6 13 0.0175 16 3 0.0047
13q+ 15 18 1.0000 15 18 0.0846 23 10  0.0501
14q− 0 6  0.0316 2 4 0.3955 5 1 0.2202
15q+ 11 6 0.1033 6 11 0.0565 12 5 0.1877
16p+ 11 3 0.0077 6 8 0.2525 11 3 0.0806
17p− 2 10 0.0592 6 6 0.7554 9 3 0.2144
18q− 7 10 0.7938 6 11 0.0565 12 5 0.1877
19p− 2 12 0.0181 5 9 0.0851 10 4 0.2486
19q− 1 4 0.3764 1 4 0.1587 2 3 0.6528
20q+ 27 29 0.3996 28 28 0.0847 39 17 0.0011
22q- 0 11 0.0009 4 7 0.1934 8 3 0.3343
Xp+ 18 5 0.0002 8 15 0.0147 19 4  0.0032
Xq- 1 5 0.2202 1 5 0.0796 6 0 0.0316
Xq+ 19 8 0.0024 10 17 0.0121 20 7 0.0231
ROM: retention of mismatch repair enzyme expression. p values  <0.05 are shown in bold.
M vs I+LN
Table 1: Differences in frequencies of chromosomal copy-number changes between clusters A and B (a), between mucosal and
invasive/metastatic samples (b), and between N0 and N1-3 (c) in ROM tumors.
a b c
Number of samples Number of samples Number of samples
N1-3 vs N0
Cluster A Cluster B Total p value
12 22 34 0.5451
8 9 17
75.35 ± 8.65 68.55 ± 7.24 0.006
3 9 12 0.0038
7 19 26 (U+M vs L)
13 6 19
≤ 2cm 1 14 15
>2cm 22 20 42
≤ 3cm 5 19 24
>3cm 18 15 33
≤ 4cm 9 26 35
>4cm 14 8 22
≤ 5cm 14 27 41
>5cm 9 7 16
T1 5 23 28
T2-4 18 11 29
N0 12 23 35
N1-3 11 11 22
LOM 5 2 7 0.1057
ROM 18 32 50
+ 0 1 1 1.0000
− 23 33 56
Diffuse/
regional/null 13 26 39 0.1497
Sporadic 10 8 18
Phenotype
Intestinal predominant 5 17 23 0.0264
17 15 32
57 tumors
Table 2: Differences in clinicopathological factors between clusters A and B.
Tumor size
0.0019
Local extension
-     Middle (M)
-     Lower (L)
0.0143
0.0062
0.1454
Gender*
-     Male
-     Female
Age* (mean ± SD)
Tumor locus
-     Upper (U)
*Tumor number is 51 after excluding 2 double cancers and 1 collision cancer (6
tumors). LOM/ROM: loss/retention of mismatch repair enzyme expression.
p values  <0.05 are shown in bold.
Mismatch repair enzyme expression
EBV infection
p53 expression
0.0011
0.2769
Nodal lymph node status
Non-intestinal
Cluster A Cluster B
Fig. 1
LOM
a
ROM
b
Cluster A (ROM) 
c
Cluster B (ROM) 
d
Fig. 2
m samples 
i samples 
ln samples
a
b
c
Cluster A (ROM) 
Cluster B (ROM)
m samples
i samples 
ln samples
f
e
d
Fig. 3
Cluster B
Cluster A
LN metastasis
LN metastasis
8q+, 20q+, 13q+ , 
5q−
Mucosal growth 
(12p/q+)
LOM
ROM
4q−, 14q−, 
19p−, 22q−
20q+,
5q−
16p+ 
7p/q+, 10p+, Xp/q+, 
3p−, 4p−, 8p-, 9p-
Extra-mucosal 
invasion
Extra-mucosal 
invasion
Fig. 4
Intramucosal neoplasm
LG/HG adenoma
AdenocarcinomaA
Stable
Unstable
Extra-mucosal invasive carcinoma
≤ 2 cm
> 2 cm
> 2 cm
Loss-rich
Gain-rich
T1 T2-4
T1 T2-4
X
Fig. 5
Samples Age Gender Locus* Size T N Excision p53 MSH6 PMS2 LOM† EBV MUC5AC MUC6 MUC2 CD10 Phenotype‡
#1 M3mr 67 F M 13 1a 0 Surgical Null + + 2+ − − − G
#2 M4mr 67 M M 30 1a 0 Surgical Diffuse + + 1+ − 1+ − G=I
#3 M5mr 74 M M 60 1a 0 Surgical Sporadic + + − − 1+ 1+ I
#4 M6mr 65 M M 25 1a 0 Surgical Diffuse + + 1+ − − − G
#5 M7mr 67 F M 25 1a 0 Surgical Diffuse + + − 1+ 1+ 1+ I>G
#6 M8mr 70 F L 35 1a 0 Surgical Null + + − − − 1+ I
#7 M9mr 51 M L 40 1a 0 Surgical Sporadic + + 1+ − 2+ - I>G
#8 M17m 59 M L 25 1a 0 Surgical Diffuse + + 2+ 2+ 1+ 2+ G>I
#9 M18m 80 F L 25 1a 0 Surgical Sporadic + + 3+ 1+ − − G
#10 M22m 76 M M 22 1a 0 Surgical Null + + 1+ 1+ 1+ − G>I
#11 M23m 65 M M 35 1a 0 Surgical Null + + 3+ 2+ − − G
#12 M24m 68 M M 25 1a 0 Surgical Diffuse + + − − 1+ 3+ I
#13 M27m 75 M M 10 1a 0 ESD** Diffuse + + − 1+ 1+ 1+ I>G
#14 M28m 58 M M 7 1a 0 ESD Diffuse + + 1+ 1+ − − G
#15 M29m 62 F M 7 1a 0 ESD Diffuse + + 1+ − − 2+ I>G
#16 M31m 81 F L 9 1b 0 ESD Diffuse + + 2+ − − − G
#17 M30m 71 M U 10 1a 0 ESD Null + + − − − 1+ I
#18 M32m 61 F U 9 1a 0 ESD Null + + − − 1+ 2+ I
#19 M33m 60 M M 8 1a 0 ESD Diffuse + + − − − − N
#20 M34m 61 M M 7 1a 0 ESD Regional + + 1+ 2+ − − G
#21 M35m 70 M U 5 1a 0 ESD Sporadic + + − − − − N
#22 M36m 67 M M 9 1a 0 ESD Diffuse + + 2+ 1+ − − G
#23 S2mr 81 F L 35 1b 1 Surgical Diffuse + + − − − 1+ I
#24 S4m 63 M L 20 1b 1 Surgical Diffuse + + − − − 1+ I
#24 S4i Diffuse + + − − − 2+ I
#24 S4ln Diffuse + + − − − 2+ I
#25 S5m 82 M U 35 1b 0 Surgical Sporadic + + − − − 3+ I
#25 S5i Sporadic + + − − − 3+ I
#26 S5m2 Sporadic + + − − − 3+ I
#26 S5ln Sporadic + + − − − 3+ I
#27 S7m 75 F M 20 1b 1 Surgical Diffuse + + − − + − I
#27 S7i Diffuse + + − − − − N
#27 S7ln Diffuse + + − − − − N
#28 S8m 64 F M 15 1b 1 Surgical Sporadic + + 2+ 1+ 1+ − G>I
#28 S8i Sporadic + + N/A¶ N/A N/A N/A N/A
#28 S8i2 Sporadic + + − − − 3+ I
#28 S8ln Sporadic + + − 2+ 1+ 3+ I>G
#29 A2mr 71 M M 100 3 0 Surgical Diffuse + + − − − 1+ I
#30 A6i 81 F M 35 3 2 Surgical Diffuse + + − − − − N
#30 A6ln Diffuse + + − − − − N
#31 A7m 79 M U 70 4a 3 Surgical Diffuse + + 1+ 2+ − − G
#31 A7i Diffuse + + − − − 1+ I
#31 A7ln Diffuse + + − − − − N
#32 A8m 69 F L 45 3 3 Surgical Sporadic + + 2+ − 1+ − G>I
#32 A8i Sporadic + + 2+ − − − G
#32 A8ln Sporadic + + 2+ − − − G
#33 A9m 67 F L 50 4a 2 Surgical Diffuse + + − − 3+ 2+ I
#33 A9i Diffuse + + 1+ − 2+ 1+ I
#33 A9ln Diffuse + + − − 2+ − I
#34 A11m 70 F M 25 2 1 Surgical Sporadic + + − − − 3+ I
#34 A11i Sporadic + + − − − − N
#35 A12i 65 F L 55 3 1 Surgical Diffuse + + − − − 3+ I
#35 A12ln Diffuse + + − − − 3+ I
#36 A13m 75 F M 43 2 1 Surgical Sporadic + − LOM − − − − N
#36 A13i Sporadic + − LOM − − − − N
#36 A13ln Sporadic + − LOM − − − − N
#37 A13m2 75 F U 45 2 0 Surgical Sporadic + − LOM 1+ − − − G
#38 A14m 77 M L 70 4a 3 Surgical Sporadic + − LOM − 3+ 3+ − G=I
#38 A14i Sporadic + − LOM − 1+ 2+ − I>G
#38 A14ln Sporadic + − LOM 3+ 1+ 2+ − G>I
#39 A15m 71 M U 95 4a 3 Surgical Null + + + − − 2+ 1+ I
#39 A15i Null + + + − − 1+ − I
#39 A15ln Null + + + − − − − N
#40 A16m 80 M L 80 3 3 Surgical Diffuse + + 1+ 1+ − − G
#40 A16i Diffuse + + − − − − N
#40 A16ln Diffuse + + − − − − N
#41 A17m1 82 M L 40 3 1 Surgical Diffuse + + − − − − N
#41 A17i1 Diffuse + + − − − 1+ I
#41 A17ln Diffuse + + − − − 3+ I
#42 A17m2 82 M M 15 2 0 Surgical Sporadic + + 1+ 1+ − − G
#42 A17i2 Sporadic + + − − − N
#43 A18m 72 M U 40 3 0 Surgical Diffuse + + − − − 3+ I
#43 A18i Diffuse + + − − − 3+ I
#44 A19m 65 M U 40 3 3 Surgical Diffuse + + − − + − I
#44 A19i Diffuse + + − − + − I
#44 A19ln Diffuse + + − − 1+ 1+ I
#45 A20m 86 M L 100 3 1 Surgical Sporadic + − LOM 3+ 1+ − − G
#45 A20i Sporadic + − LOM 3+ 1+ − − G
#45 A20ln Sporadic + − LOM 3+ 3+ − − G
#46 A21m 79 M M 45 4a 2 Surgical Regional + + − 1+ − 3+ I>G
#46 A21i Regional + + − − − 3+ I
#46 A21ln Regional + + − − − 3+ I
#47 A22m 85 M M 60 3 3a Surgical Diffuse + + − − 1+ − I
#47 A22i Diffuse + + − − − − N
#47 A22ln Diffuse + + 1+ − − − G
#48 A23m 70 M M 30 2 0 Surgical Diffuse + + 1+ − − − G
#48 A23i Diffuse + + − − − − N
#49 A26i 86 F L 85 3 2 Surgical Sporadic + − LOM 2+ − − − G
#49 A26ln Sporadic + − LOM 2+ 1+ − − G
#50 A28m 85 M M 95 3 >1 Surgical Null + + 2+ 1+ 1+ − G>I
#50 A28i Null + + 3+ 1+ 2+ − G>I
#50 A28ln Null + + 3+ − 1+ − G>I
#50 A28m2 Null + + 2+ 1+ 1+ − G>I
#50 A28i2 Null + + 2+ 2+ 2+ − G>I
#51 A29m 86 M M 31 3 0 Surgical Diffuse + + − − − 2+ I
#51 A29i Diffuse + + − − − − N
#52 A30m 78 F L 48 3 0 Surgical Diffuse + + 1+ − − − G
#52 A30i Diffuse + + − − − − N
#52 A30m2 Diffuse + + − 2+ 1+ − G>I
#53 A31m 80 M U 56 3 0 Surgical Regional + + − − − 3+ I
#53 A31i Regional + + 2+ − − − G
#54 A32m 71 M L 60 4b 0 Surgical Sporadic + + 3+ − − − G
#54 A32i Regional + + − − − − N
#55 A33i 72 M L 120 3 0 Surgical Sporadic + − LOM 1+ 2+ − − G
#56 A34i 57 M L 60 3 0 Surgical Sporadic + − LOM − − − − N
#57 A35i 72 M U 60 2 0 Surgical Diffuse + + 3+ 3+ − 1+ G>I
Online suppl. Table 1: Clinicopathological features of individual tumors (age, gender, locus, size of mucosal lesion, pT, pN, and excision type). and immunohistochemical
and in situ hybridization results (p53, MMR enzymes, EBV, mucin markers) of individual samples.
*Locus: "U"/"M"/"L", upper/middle/lower one third of the stomach. **ESD: endoscopic submucosal dissection. †LOM: Loss of mismatch repair enzyme expression. ‡
Phenotype: "G"/"I"/"N", gastric/intestinal/null. ¶N/A: not assessable.
Tumor N.
Cluster A
(n = 51 )
Cluster B
(n = 5 5) p value
Cluster A
(n = 51 )
Cluster B
(n = 5 5) p value
AATK 8 13 0.3388 1 0 0.4811
ALK 6 4 0.516 0 0 1
AXL 15 3 0.0014 1 0 0.4811
CSF1R 10 12 0.8148 0 1 1
DDR1 20 19 0.6887 3 3 1
DDR2 16 19 0.8368 2 0 0.2291
FGFR1 13 12 0.8193 2 1 0.6074
FGFR2 5 12 0.1155 0 1 1
FGFR3 21 17 0.314 8 4 0.2249
FGFR4 17 8 0.0381 3 1 0.3495
FLT1(VEGFR1) 25 19 0.168 5 1 0.1033
FLT3 16 23 0.3158 3 0 0.1079
FLT4 (VEGFR3) 19 14 0.2131 1 0 0.4811
IGF1R 16 6 0.0154 2 0 0.2291
INSR 3 2 0.6699 0 0 1
INSRR N/A N/A N/A N/A N/A N/A
KDR (VEGFR2) 4 2 0.4248 1 0 0,.811
KIT 6 3 0.3075 1 0 0.4811
LMTK2 29 15 0.003 7 0 0.0048
LMTK3 N/A N/A N/A N/A N/A N/A
LTK N/A N/A N/A N/A N/A N/A
MERTK 14 12 0.6519 0 1 1
MET 18 11 0.0861 0 1 1
MST1R 17 7 0.0191 1 0 0.4811
MUSK 13 9 0.3382 0 0 1
NTRK1 13 17 0.6667 1 1 1
NTRK2 9 7 0.5901 0 0 1
NTRK3 14 4 0.0086 0 0 1
PDGFRA 4 3 0.7086 0 0 1
PDGFRB 7 8 1 0 0 1
PTK7 22 21 0.6932 13 10 0.48
RET 19 19 0.8405 2 7 0.1636
ROR1 5 6 1 0 0 1
ROR2 7 3 0.1905 0 0 1
ROS1 10 2 0.0129 0 0 1
RYK 9 3 0.0661 0 0 1
STYK1 29 20 0.0508 8 3 0.114
TEK 3 3 1 0 0 1
TIE1 13 22 0.1484 5 2 0.2575
TYRO3 17 15 0.5313 1 1 1
EPHA1 6 7 1 0 0 1
EPHA2 16 14 0.5248 0 0 1
EPHA3 14 4 0.0086 0 0 1
EPHA4 9 5 0.2544 0 0 1
EPHA5 3 8 0.2052 0 0 1
EPHA6 6 5 0.755 0 0 1
EPHA7 3 2 0.6699 0 0 1
EPHA8 6 12 0.2018 2 0 0.2291
EPHA10 26 29 1 11 14 0.6554
EPHB1 9 5 0.2544 0 0 1
EPHB2 21 24 0.8457 2 1 0.6074
EPHB3 24 15 0.0444 8 2 0.0464
EPHB4 28 20 0.0786 14 5 0.0212
EPHB6 32 27 0.1755 14 7 0.0867
EGFR 20 7  0.0033 6 1 0.0537
ERBB2 28 32 0.8449 7 13 0.2219
ERBB3 17 8 0,.0381 7 3 0.1905
ERBB4 6 1 0.0537 0 0 1
RALA 18 9 0.0283 2 0 0.2291
PTPN12 16 9 0.1079 4 0 0.0503
MAFK 34 25 0.0328 23 15 0.0693
ARHGEF5 17 15 0.5313 5 3 0.4772
BRAF 11 9 0.6206 1 0 0.4811
CAV1 12 8 0.3213 1 0 0.4811
GLI3 25 11 0.0021 1 0 0.4811
HOXA1 29 32 1 4 3 0.7086
RABL5 21 13 0.063 4 3 0.7086
RBM28 22 21 0.6932 8 7 0.7826
CUL1 31 20 0.0192 11 3 0.0203
IGF2BP3 25 19 0.168 3 2 0.6699
RELB 25 17 0.0741 3 0 0.1079
SEMA3E 19 7 0.006 1 0 0.4811
p values <0.05 are shown in bold. N/A: not assessable.
Name of Gene
Online suppl. Table 2: Frequencies of copy-number gains and amplifications of receptor tyrosine kinases and
representative growth-related genes on chromosome 7 in clusters A and B.
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M I+LN M I+LN
Cluster A Cluster B
I + I>G
G + G≥I
N
G + G≥I N p value
A M 12 2 0.0392
I+LN 12 12
B M 13 2 0.0062
I+LN 2 6
A+B M 25 4 0.0011
I+LN 14 18
A 24 14 1.0000 
B 15 8
I + I>G Non-I p value
A M 6 14 0.7432
I+LN 7 24
B M 18 15 0.7784
I+LN 13 8
A+B M 24 29 0.5545
I+LN 20 32
A 13 38 0.0014
B 31 23
a
c
b
Online suppl. Fig. 2
Online suppl. Fig. 3
No Genesymbol Gene name Gene function Location
Probe
number Cluster A Cluster B p  value
p  value
after BC¶
1 VRK2 vaccinia related kinase 2 apoptosis and growth 2p16.1 4 0.2216578 -0.091428 1.78882E-06 0.026791191
2 XIRP2 xin actin binding repeat containing 2 actin binding 2q24.3 8 0.2525296 0.0062581 1.27706E-06 0.019126541
3 CNTN6 contactin 6 cell adhesion 3p26.3 6 0.00099 -0.322622 8.6214E-07 0.012912274
4 CNTN4 contactin 4 axon connections 3p26.3-p26.2 19 0.1137656 -0.189603 2.02011E-09 3.02551E-05
5 RBMS3 RNA binding motif single stranded interacting protein 3 c-myc gene binding 3p24.1 16 0.0883685 -0.259709 1.30358E-12 1.95238E-08
6 ARPP-21 cAMP regulated phosphoprotein 21 nerve function 3p22.3 5 0.1407465 -0.211016 3.69533E-07 0.005534503
7 STAC SH3 and cysteine rich domain SH3 and cysteine rich 3p22.3-p22.2 4 0.0944739 -0.24017 5.63687E-07 0.008442343
8 MYRIP myosin VIIA and Rab interacting protein myosin interacting 3p22.1 10 0.1020163 -0.178061 1.24906E-06 0.018707211
9 CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3tumor suppressor gene 3p21.1-p14.3 20 0.1946772 -0.121071 3.18111E-08 0.000476436
10 PTPRG protein tyrosine phosphatase, receptor type G tumor suppressor gene 3p14.2 14 0.0442553 -0.238805 3.32493E-06 0.049797535
11 LRIG1 leucine rich repeats and immunoglobulin like domains 1 tumor suppressor gene 3p14.1 3 0.2577084 -0.234233 1.39033E-06 0.020822901
12 SLIT2 slit guidance ligand 2 tumor suppressor gene 4p15.31 11 0.0410187 -0.214485 1.32879E-06 0.019901247
13 SEL1L3 SEL1L family member 3 lymph node/stomach expression 4p15.2 3 0.1200379 -0.272848 5.63456E-07 0.00843888
14 FSTL5 follistatin like 5 tumor suppressor gene 4q32.2 16 0.0087773 -0.252876 1.05674E-06 0.015826866
15 GPM6A glycoprotein M6A oncogenic potential gene 4q34.2 9 0.1142247 -0.225603 2.75025E-07 0.004119045
16 MCCC2 methylcrotonoyl-CoA carboxylase 2 carboxylase 5q13.2 3 0.1370447 -0.323169 2.31579E-07 0.003468354
17 NXPH1 neurexophilin 1 nerve function 7p21.3 6 0.4400862 0.0622393 6.47209E-07 0.009693249
18 H2AFV H2A histone family member V histones nucleosome 7p13 2 0.6194794 0.1092316 8.29559E-07 0.012424304
19 SUN3 Sad1 and UNC84 domain containing 3 testis expression 7p12.3 2 0.3635659 -0.120918 8.55676E-07 0.012815461
20 COBL cordon-bleu WH2 repeat protein actin regulator 7p12.1 8 0.4966139 0.111728 4.98461E-08 0.000746545
21 SEMA3E semaphorin 3E proto-oncogene? 7q21.11 7 0.2570146 -0.078017 1.71778E-06 0.025727224
22 MUC12 mucin 12, cell surface associated tumor suppressor gene 7q22.1 2 0.7944379 0.2106728 8.58551E-08 0.001285852
23 ORAI2 ORAI calcium release-activated calcium modulator 2 calcium modulator 7q22.1 2 0.370068 -0.099438 3.29493E-07 0.004934813
24 PRKD1 protein kinase D1 target for oncogenic KRas signaling 14q12 9 0.0830602 -0.212465 1.15426E-06 0.017287292
25 SLC39A9 solute carrier family 39 member 9 proto-oncogene 14q24.1 3 0.2246334 -0.265776 2.34539E-08 0.000351268
26 NRXN3 neurexin 3 nerve function 14q24.3-q31.1 29 -0.009645 -0.199779 1.05375E-06 0.015782062
27 CHST14 carbohydrate sulfotransferase 14 sulfotransferases 15q15.1 1 0.5904759 -0.107594 2.16714E-06 0.032457219
28 HS3ST3A1 heparan sulfate-glucosamine 3-sulfotransferase 3A1 tumor growth factor related gene 17p12 5 0.1581726 -0.186387 2.87768E-06 0.043099021
29 MAP2K7 mitogen-activated protein kinase kinase 7 tumor growth factor related gene 19p13.2 2 0.3651435 -0.067787 3.70778E-07 0.005553136
30 SCUBE1 signal peptide, CUB domain and EGF like domain containing 1  EGF (epidermal growth factor)-like 22q13.2 4 0.0642863 -0.256986 5.19618E-07 0.007782325
31 MPPED1 metallophosphoesterase domain containing 1 brain/liver expression 22q13.2 3 0.482682 -0.047041 1.24649E-07 0.001866868
32 CELSR1 cadherin EGF LAG seven-pass G-type receptor 1 non-classic-type cadherin 22q13.31 4 0.0170639 -0.325309 2.06694E-06 0.030956486
*T/R: Tumor/Reference fluorescence intensity ratio.  ¶BC: Bonferroni corretion.
Difference  (A vs B)Mean T/R*
